| Farmacoterapia para la obesidad: pasado, presente y futuro |
Pharmacotherapies for obesity: past, current, and future therapies.
Ioannides-Demos LL, Piccenna L, McNeil JJ.
Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, Australia.
J Obes. 2011;2011:179674. Epub 2010 Dec 12.
Abstract
Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide)........http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006492/pdf/JOBES2011-179674.pdf
|
| Fármacos presentes y futuros en el manejo del peso |
Current and future drug targets in weight management.
Witkamp RF.
Division of Human Nutrition, Wageningen University, P.O. Box 8129, 6700 EV Wageningen, The Netherlands. renger.witkamp@wur.nl
Pharm Res. 2011 Aug;28(8):1792-818. Epub 2010 Dec 23.
Abstract
Obesity will continue to be one of the leading causes of chronic disease unless the ongoing rise in the prevalence of this condition is reversed. Accumulating morbidity figures and a shortage of effective drugs have generated substantial research activity with several molecular targets being investigated. However, pharmacological modulation of body weight is extremely complex, since it is essentially a battle against one of the strongest human instincts and highly efficient mechanisms of energy uptake and storage. This review provides an overview of the different molecular strategies intended to lower body weight or adipose tissue mass. Weight-loss drugs in development include molecules intended to reduce the absorption of lipids from the GI tract, various ways to limit food intake, and compounds that increase energy expenditure or reduce adipose tissue size. A number of new preparations, including combinations of the existing drugs topiramate plus phentermine, bupropion plus naltrexone, and the selective 5-HT(2C) agonist lorcaserin have recently been filed for approval. Behind these leading candidates are several other potentially promising compounds and combinations currently undergoing phase II and III testing. Some interesting targets further on the horizon are also discussed.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130908/pdf/11095_2010_Article_341.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130908/?tool=pubmed
|
|
No hay comentarios:
Publicar un comentario